Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis is to move two anticancer compounds and one diabetic kidney disease drug into phase II trials. The three drugs represent the three most advanced internally developed compounds that the company currently has in its pipeline.
Subscribe to our email newsletter
The company intends to begin a phase II program on its anticancer compounds, with the working names XL999 and XL647, before the end of this year, with results from these tests anticipated in 2006.
XL999 is to be studied in multiple solid tumor types including renal cell carcinoma, colorectal, non-small cell lung, and ovarian cancers. In addition, it will be investigated in hematological malignancies.
XL647 is orally bio-available in humans and a tablet dosage form has been developed for use in phase II studies. XL647 is expected to enter initially into trials in patients with non-small cell lung cancer and breast cancer, tumors where the kinases inhibited by XL647 are known to play a role.
The diabetic nephropathy drug is currently known as XL784. The planned study into this drug will evaluate the safety and general effects in humans of XL784 when it is administered daily for 2 weeks using a newly-developed capsule formulation. After successful completion of the multi-dose phase I trial, the company plans to initiate a phase II study to test the ability of XL784 to treat patients with proteinuria associated with diabetic kidney disease.